Creative Diagnostics Expands Hepatic Metabolism Product Line to Enhance Drug Development Research

Creative Diagnostics, a reagent supplier focused on biologics quality control, has announced the expansion of its comprehensive range of Products for Hepatic Metabolism. This new line of liver-specific fractions, including Liver Cytosol, Liver Microsomes, and Liver S9 Fractions, comes from various species and can support pharmaceutical researchers and toxicologists in conducting critical in vitro metabolism studies. The liver plays a central role in human metabolism, processing both beneficial and harmful substances through carbohydrate metabolism, lipid and fatty acid metabolism, protein and amino acid metabolism, and drug metabolism. Most liver diseases result in varying degrees of hepatocyte damage and functional impairment, thereby profoundly affecting these metabolic processes.

The liver is the primary organ for drug metabolism and the main site of drug-induced toxicity, accounting for over 50% of acute liver failure cases that lead to the withdrawal or restricted use of approved medications. Beyond hepatotoxicity, metabolites generated in the liver circulate systemically to other tissues and organs, including the kidneys, heart, brain, intestines, and lungs, as well as tumors. Harnessing drug-metabolite interactions between the liver and other organs can achieve desired therapeutic effects, but such interactions may also lead to unintended toxic side effects. For example, the pre-chemotherapy drug ifosfamide induces nephrotoxicity because in addition to producing the intended antitumor metabolite, 4-hydroxy-IFO, the liver generates the nephrotoxic metabolite chloroacetaldehyde. Therefore, interactions between the liver and other organs must be carefully considered and evaluated in drug metabolism and toxicity studies.

Creative Diagnostics now offers an extensive range of hepatic metabolism related products that enable researchers to study hepatic metabolic processes with high precision and reproducibility. This new product line includes liver products from various species, such as humans, non-human primates, dogs, rats, rabbits, and minipigs. Core products include Liver Cytosol, Liver Microsomes, and Liver S9 Fractions. The company can provide comprehensive metabolic research solutions to address challenges encountered during drug development. A Creative Diagnostics project manager stated that precise metabolomic analysis is the cornerstone of successful drug development, and by offering a liver metabolism testing product line spanning multiple species, they help clients in the pharmaceutical industry bridge the gap between in vitro testing and in vivo outcomes, ultimately reducing the risk of clinical failure.

Drug metabolism studies are essential during the evaluation of drugs, and researchers can learn more about the full catalog of Products for Hepatic Metabolism by visiting https://qbd.creative-diagnostics.com/products-for-hepatic-metabolism.html. This expansion matters because it addresses a critical need in pharmaceutical research where accurate prediction of drug metabolism and toxicity in humans remains challenging. The availability of liver fractions from multiple species allows for more comprehensive cross-species comparisons, which is particularly important given that drug metabolites generated in the liver can affect distant organs and tissues. This development has significant implications for drug safety assessment, as it enables researchers to better predict potential toxicities before clinical trials, potentially reducing late-stage drug failures and improving patient safety. The expanded portfolio supports the pharmaceutical industry's ongoing efforts to develop safer and more effective medications by providing tools that enhance the accuracy of preclinical testing.